# PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

> **NCT03647072** · PHASE3 · RECRUITING · sponsor: **Sherief Abd-Elsalam** · enrollment: 60 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** CHOP
- **DRUG:** CHOP Plus Lanzoprazole
- **DRUG:** CHOP Plus Famotidine

## Key facts

- **NCT ID:** NCT03647072
- **Lead sponsor:** Sherief Abd-Elsalam
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-08-01
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03647072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03647072, "PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03647072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*